Remembering a Giant: R. Palmer Beasley

Dr. R. Palmer Beasley's passing is a tremendous loss for the hepatitis community. He was a member of CEVHAP and Palmer and I were friends for nearly 40 years. I knew him very well, because he worked in Taiwan in 1970-80's and we both had a common interest in hepatitis research. He contributed a lot to our understanding of the epidemiology of hepatitis B, the etiologic role of hepatitis B virus (HBV) in hepatocellular carcinoma (HCC), and the immunoprophylaxis of HBV infection. His landmark discovery of "vertical" transmission of HBV from carrier mothers to their infants in early 1970's paved the road of hepatitis B vaccination. Indeed, he and colleagues went on to show the efficacy of hepatitis B immune globulin and hepatitis B vaccine in this setting, which laid the foundation of hepatitis B immunization in newborns. It is now a regular practice worldwide and this will avert millions of deaths due to end-stage liver disease and HCC.

Although the control of hepatitis B is on the right track, there are still many hurdles in its implementation. While CEVHAP is working toward the eradication of viral hepatitis in our region, we will all remember the giant who has contributed so much to what we are doing now.

D S Chen

An article in The New York Times:
R. Palmer Beasley, Expert on Hepatitis B, Dies at 76

Australian Specialist Develops New Tools for the Fight Against Hepatitis B

Liverpool Hospital, Sydney NSW, at the launch of a set of innovative educational resources designed to improve the treatment rates of Australia’s approximately 170,000 hepatitis B sufferers and reduce the incidence of hepatitis B-related liver cancer and liver failure:

L to R:
Professor Stephen Locarnini, Director, World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B at the Victorian Infectious Diseases Reference Laboratory; Dr Kerry Chant, Chief Health Officer, NSW; Dr Miriam Levy, Head of Gastroenterology and Hepatology at Liverpool Hospital in Sydney

For more details:
CEVHAP - NSW Health Joint Press Release, 23 July 2012

CEVHAP Policy Symposium at APASL

At the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL) held in Taipei, on 19 February 2012, CEVHAP staged its first symposium entitled: “Better health through better public policies – What we can learn from the HIV experience.”

Keynote speaker, Dr David Thomas, of Johns Hopkins School of Medicine in the USA, presented some compelling data emphasising the comparatively large number of deaths occurring as a result of viral hepatitis infection as opposed to the small amount of funding received by the sector - from both public and private sources . The Symposium highlighted the need to build far better public awareness about viral hepatitis and also the need for adequate surveillance data, lacking in many countries, upon which to build and develop sound policy responses.

Some key media articles following the symposium:

Express Pharma (India) Online, 16-31 March 2012
CEVHAP hosts agenda-setting meet on hepatitis policy

South China Morning Post, 13 March 2012
Going viral; Break the silence; Lessons from an earlier battle

South China Morning Post, 21 February 2012
A silent killer remains at large

FaLang translation system by Faboba



APASL 2017


CEVHAP Asia Pacific Hepatitis Policy 2016 Survey finds Asia Pacific on path to eliminating viral hepatitis
APASL 2016


WHD 2015

Linkage between screening and treatment needed to improve hepatitis care in China 




WHD 2014
APASL 2014


WHD 2013

APASL 2013

CEVHAP welcomes the launch and dedicates their support to the Global Hepatitis Network 


WHD 2012

CEVHAP WHD 2012 Press Release
CEVHAP-NSW Health Joint
Press Release in Australia
APASL 2012
CEVHAP Symposium Announcement 


WHD 2011
China (Chinese)
Indonesia (Bahasa)
Press Release in Korea (Korean)
Hong Kong (English)
Hong Kong (Chinese)
Connect with usconnect with CEVHAP